Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding
genomic landscapes and biological functions, the treatment of PCa continues to improve …

Simple Summary The present review highlights and examines the importance of animal
models in relevant topics concerning current human and animal health. Over the past five …

Immune checkpoint therapy (ICT) shows encouraging results in a subset of patients with
metastatic castration-resistant prostate cancer (mCRPC) but still elicits a sub-optimal …

Metastatic castration-resistant prostate cancer (PC) is the final stage of PC that acquires
resistance to androgen deprivation therapies (ADT). Despite progresses in understanding of …

Bone metastasis is the main cause of death in patients with prostate cancer (PCa), but there
lacks effective treatment method. Immunotherapy shows new hopes for bone metastatic PCa …

During disease progression from primary towards metastatic prostate cancer (PCa), and in
particular bone metastases, the tumor microenvironment (TME) evolves in parallel with the …

Solid cancers comprise a large number of new cases and deaths from cancer each year
globally. There are a number of strategies for addressing tumors raised from solid organs …

Recently, the overall survival (OS) and progression-free survival (PFS) of patients with
advanced cancer has been significantly improved due to the application of immune …

The consequences of prostate cancer metastasis remain severe, with huge impact on the
mortality and overall quality of life of affected patients. Despite the convoluted interplay and …

Bone metastasis is a major cause of morbidity in persons with cancer. Complications include
pain, impaired mobility, pathological fracture, spinal cord compression, cranial nerve …